Pay in 4 interest-free payments of $5.76 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Retatrutide , a triple agonist targeting GLP-1, GIP, and glucagon receptors, has shown impressive results in clinical trials with weight loss exceeding 24% in some studies
This means that a licensed healthcare provider must authorize the use of this medication
Some advancements include: Wearable devices that track physical activity and caloric intake
A 2022 study in rats with induced osteoarthritis found that GLP-1 receptor activation reduced cartilage degradation, decreased synovial inflammation, and lowered concentrations of matrix metalloproteinase-13, a key enzyme in cartilage breakdown
This option has been more affordable and accessible for patients
